Lytix, Kael Co. Ltd. deal

Kael's Kael-GemVax Co. Ltd. subsidiary and Lytix will jointly conduct a Norwegian Phase I trial combining Lytix's LTX-315 and Kael-GemVax's GV1001 to treat cancer. Lytix is responsible for conductin...